CVS Health Corporation (NYSE:CVS) Stake Decreased by Armbruster Capital Management Inc

Paterniano Del Favero
Agosto 4, 2017

It dropped, as 135 investors sold CVS shares while 627 reduced holdings.

Covington Capital Management decreased its stake in C V S Corp (CVS) by 28.3% based on its latest 2016Q4 regulatory filing with the SEC. It worsened, as 135 investors sold CVS shares while 627 reduced holdings. Alpha Windward LLC boosted its stake in shares of CVS Health Corporation by 1.5% in the first quarter. Meadow Creek Investment Management LLC now owns 126,820 shares of the pharmacy operator's stock valued at $9,955,000 after buying an additional 36,788 shares during the last quarter. Ipswich Management Company holds 0.35% in CVS Health Corp (NYSE:CVS) or 9,793 shares. The Schmidt P J Investment Management Inc holds 15,166 shares with $1.20 million value, down from 20,229 last quarter. Teza Capital Management LLC acquired a new stake in CVS Health Corporation during the first quarter valued at about $803,000. Lee Danner & Bass Inc. raised its stake in CVS Health Corporation by 4.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 16,122 shares of the pharmacy operator's stock valued at $1,266,000 after buying an additional 90 shares during the period. Cue Financial Group Inc sold 4,337 shares as Cvs Health Corp (CVS)'s stock declined 4.23%. Cue Financial Group Inc. now owns 2,708 shares of the pharmacy operator's stock valued at $213,000 after buying an additional 95 shares during the period. Richard Bernstein Advsrs Ltd Limited Liability Company, a New York-based fund reported 8,391 shares.

CVS Health Corporation (NYSE CVS) traded down 1.44% during mid-day trading on Thursday, reaching $78.60. CVS Health Corporation has a 12 month low of $69.30 and a 12 month high of $98.44. The stock has a market capitalization of $80.08 billion, a PE ratio of 16.39 and a beta of 0.91. The stock's 50 day moving average price is $78.75 and its 200-day moving average price is $79.09.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, May 2nd. The pharmacy operator reported $1.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.07. The firm had revenue of $44.51 billion for the quarter, compared to analyst estimates of $44.20 billion. The Arizona-based Papp L Roy & Associates has invested 0.32% in CVS Health Corp (NYSE:CVS). About shares traded. CVS Health Corp (NYSE:CVS) has declined 24.40% since August 3, 2016 and is downtrending. During the same period previous year, the firm posted $1.18 EPS. Analysts expect that CVS Health Corporation will post $5.87 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 3rd. Bremer Trust Association invested in 0.61% or 28,176 shares. This represents a $2.00 annualized dividend and a yield of 2.54%. (GRUB) to Outperform" published on July 12, 2017 as well as Seekingalpha.com's news article titled: "Making Sense Of The Groupon-Grubhub Deal" with publication date: "August 01, 2017. The stock of CVS Health Corp (NYSE:CVS) has "Outperform" rating given on Wednesday, August 5 by RBC Capital Markets.

COPYRIGHT VIOLATION NOTICE: "CVS Health Corporation (NYSE:CVS) Stake Decreased by Armbruster Capital Management Inc." was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another domain, it was stolen and republished in violation of US & worldwide trademark and copyright laws. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/08/03/cvs-health-corporation-nysecvs-stake-decreased-by-armbruster-capital-management-inc.html.

Several equities research analysts recently issued reports on the company. Tigress Financial began coverage on shares of CVS Health Corporation in a research report on Thursday, April 27th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company's stock. Vetr upgraded shares of CVS Health Corporation from a "buy" rating to a "strong-buy" rating and set a $85.96 price target on the stock in a research report on Wednesday, May 17th. Evercore ISI restated an "outperform" rating and set a $88.00 price target (up from $87.00) on shares of CVS Health Corporation in a research report on Wednesday, May 3rd. ValuEngine downgraded shares of CVS Health Corporation from a "buy" rating to a "hold" rating in a research note on Friday, June 2nd. On Thursday, November 19 the stock rating was maintained by Brean Capital with "Buy". The stock of CVS Health Corp (NYSE:CVS) has "Neutral" rating given on Monday, February 6 by Atlantic Securities. Also, EVP Helena Foulkes sold 20,332 shares of CVS Health Corporation stock in a transaction dated Monday, June 19th. Following the completion of the sale, the executive vice president now owns 59,301 shares in the company, valued at approximately $4,744,080.

In other news, CFO David M. Denton sold 230,510 shares of the firm's stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $80.00, for a total transaction of $18,440,800.00. Following the completion of the sale, the chief financial officer now owns 176,983 shares of the company's stock, valued at approximately $14,158,640. The disclosure for this sale can be found here. 23,849 shares valued at $1.88 million were sold by Brennan Troyen A on Tuesday, March 21.

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Firm provides pharmacy care for the senior community through Omnicare, Inc. and Omnicare's long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE